Zhejiang TaiMed Medical Technology Co., Ltd ("TaiMed Medical Technology") was founded in 2013. TaiMed Medical Technology is a leading provider of digital solutions for the life sciences industry based on cloud computing and big data technology, with products and services covering clinical research, pharmacovigilance, pharmaceutical marketing and other areas. The company's products and services cover clinical research, pharmacovigilance, pharmaceutical marketing and other areas. With the core concept of collaboration, Tamei Medical Technology creates a collaborative digital environment for pharmaceutical companies/sponsors, hospitals/clinical research institutes, third-party service providers (CROs, SMOs, central laboratories, cold-chain logistics companies, etc.), doctors/researchers, patients/subjects and other industrial chain parties, and helps to form a healthy, prosperous, and highly efficient ecology in the pharmaceutical industry, and has become an important support platform for Chinese pharmaceutical companies to realize independent innovation.
Leading technology cast core competitiveness
It is understood that, TaiMed Medical Technology in the active use of cutting-edge cloud computing and big data technology to construct the cloud SaaS service at the same time, but also in the active development and application of data security storage technology, medical intelligent image display technology, medical intelligent image analysis technology, Chinese medical information extraction technology and other types of underlying technology. technology, medical intelligent image display technology, medical intelligent image analysis technology, Chinese medical information extraction technology and other underlying technologies. At the same time, TaiMed has built a low-code rapid development platform for the pharmaceutical industry, which effectively supports TaiMed's rapid experimentation and innovation in various scenarios. In addition, in order to adapt to the current IT development situation of Chinese enterprises and the needs of overseas business, TaiMed is also actively applying multi-cloud deployment, containerization technology, and various cloud computing security technologies to adapt to the enterprise's own IT infrastructure as well as the information compliance requirements of various countries that will be faced by the business overseas in the future.
Since its inception, Trimet has had a clear positioning of its business, focusing on the digital upgrading and transformation of the pharmaceutical industry, launching the TrialOS pharmaceutical R&D collaboration platform to connect different market players, and self-developed SaaS products covering pharmaceutical R&D, pharmacovigilance, and pharmaceutical marketing scenarios. Compared with competitors in the market who develop technology solutions for a certain segment, TaiMed can meet the diversified needs of customers in a one-stop manner. The interconnected TrialOS platform facilitates the use of customers, improves efficiency, avoids the inconvenience of manual updating caused by the lack of connectivity between different software, and has strong competitiveness in the business. At the same time, different products*** share customers and infrastructure, which not only reduces the cost of sales, improves sales coverage and customer payment potential, but also reduces operating costs.
Brand Advantage Creates a Benchmark Enterprise
Since its inception, TaiMed has continuously optimized its business, and gained high recognition from the market and customers for its professional product lines and high-quality services. As of June 30, 2021, TaiMed has done business with about 1,000 domestic and international pharmaceutical companies and CROs, and provided digital solutions to more than 360 hospitals/clinical research institutes, and has built up a good brand awareness and reputation.
In addition, TaiMed has been selected as one of the "2021 Hurun Global Unicorns" and "2020 Hurun Global Unicorns", as well as one of the "2021 China's Top 100 Digital Healthcare Enterprises - Pharmaceuticals" in the "2021 China's Top 100 Digital Healthcare Enterprises - Pharmaceuticals" list by EEOC EqualOcean. Top 10 Digital Healthcare Enterprises - Pharmaceutical Digitization Enterprises in 2021 China" and "2021 China Healthcare Unicorn List", "CB Insights Top 150 Most Promising Digital Healthcare Enterprises in the World", and was selected in the clinical research field. It is the only Chinese company in the clinical research field, and was ranked 13th in the "2019 China SaaS Enterprise Top 100 Chart" by Internet Week and eNet Research Institute, which has established a good image for TaiMed in the industry and helped TaiMed to attract customers and talents continuously. This has established a good image for TAMI in the industry, which helps to attract customers and talents.
Talent Advantage Enables Industry Development
At the same time, TaiMed has a cross-border team consisting of professionals in the pharmaceutical field and talents in the Internet field***, and the main research and development team members are from the industry's well-known TaiMed, which has sufficient talent reserves to support its business network and service quality. Tamei Medical Technology has established a comprehensive talent training, assessment and incentive mechanism to ensure the high quality, high availability, high reliability and high security of its digital solutions. The investment in human capital will bring long-term benefits to TaiMed, drive TaiMed's continuous change and innovation, and lead the development of the pharmaceutical digitalization industry.
Pharmaceutical industry digital solutions have a strong professionalism, customers need to pay a high cost of learning and transfer costs, product substitutability is not high, in the formation of the habit of use tend to use the same product for a long time, the accumulation of data will further reduce the possibility of competitors to replace. As a leading provider of pharmaceutical digital solutions in the domestic medical technology, has formed a good customer base, has a certain first-mover advantage, rich practical experience makes the product capable of a variety of business scenarios, so that too much medical technology can occupy more market share, is expected to maintain a leading position in the industry for a long time.
Tamei Medical Technology said it will continue to "make good medicine within reach" as its mission, adhere to the principle of self-research of core technologies, accelerate the company's original core product upgrades and new product development process, and strive to become a leading enterprise in the domestic pharmaceutical digitalization industry. With collaboration as the core concept, we create a collaborative digital environment for pharmaceutical companies/sponsors, hospitals/clinical research institutes, third-party service providers (CROs, SMOs, central laboratories, cold-chain logistics companies, etc.), doctors/researchers, patients/subjects and other parties in the industry chain, helping to form a healthy, prosperous and efficient pharmaceutical industry ecosystem.